104 related articles for article (PubMed ID: 10404639)
1. Determination of mRNA, and protein levels of p53, MDM2 and protein kinase CK2 subunits in F9 cells after treatment with the apoptosis-inducing drugs cisplatin and carboplatin.
Siemer S; Ornskov D; Guerra B; Boldyreff B; Issinger OG
Int J Biochem Cell Biol; 1999 Jun; 31(6):661-70. PubMed ID: 10404639
[TBL] [Abstract][Full Text] [Related]
2. Characterization of protein kinase CK2 protein subunits and p53 in F9 teratocarcinoma cells in the absence and presence of cisplatin.
Küpper M; Köster M; Schmidt-Spaniol I; Wagner-Gillen I; Issinger OG
Cell Mol Biol Res; 1994; 40(5-6):587-92. PubMed ID: 7735333
[TBL] [Abstract][Full Text] [Related]
3. p53 and the ribosomal protein L5 participate in high molecular mass complex formation with protein kinase CK2 in murine teratocarcinoma cell line F9 after serum stimulation and cisplatin treatment.
Guerra B; Issinger OG
FEBS Lett; 1998 Aug; 434(1-2):115-20. PubMed ID: 9738462
[TBL] [Abstract][Full Text] [Related]
4. Mdm2 sensitizes MCF7 breast cancer cells to cisplatin or carboplatin.
Smith ML
Breast Cancer Res Treat; 1999 Nov; 58(2):99-105. PubMed ID: 10674873
[TBL] [Abstract][Full Text] [Related]
5. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
Piovesan B; Pennell N; Berinstein NL
Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells.
Hjerrild M; Milne D; Dumaz N; Hay T; Issinger OG; Meek D
Biochem J; 2001 Apr; 355(Pt 2):347-56. PubMed ID: 11284721
[TBL] [Abstract][Full Text] [Related]
7. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
8. The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation.
Guerra B; Götz C; Wagner P; Montenarh M; Issinger OG
Oncogene; 1997 Jun; 14(22):2683-8. PubMed ID: 9178766
[TBL] [Abstract][Full Text] [Related]
9. The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells.
Di Felice V; Lauricella M; Giuliano M; Emanuele S; Vento R; Tesoriere G
Int J Oncol; 1998 Aug; 13(2):225-32. PubMed ID: 9664115
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells.
Huang H; Huang SY; Chen TT; Chen JC; Chiou CL; Huang TM
J Cell Biochem; 2004 Mar; 91(4):756-65. PubMed ID: 14991767
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.
Pääjärvi G; Roudier E; Crisby M; Högberg J; Stenius U
FASEB J; 2005 Mar; 19(3):476-8. PubMed ID: 15625077
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
Sasaki H; Sheng Y; Kotsuji F; Tsang BK
Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
[TBL] [Abstract][Full Text] [Related]
13. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
14. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
Roh JL; Park JY; Kim EH
Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
[TBL] [Abstract][Full Text] [Related]
15. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis.
Kondo S; Barnett GH; Hara H; Morimura T; Takeuchi J
Oncogene; 1995 May; 10(10):2001-6. PubMed ID: 7761100
[TBL] [Abstract][Full Text] [Related]
16. Wild-type p53 inhibits protein kinase CK2 activity.
Schuster N; Götz C; Faust M; Schneider E; Prowald A; Jungbluth A; Montenarh M
J Cell Biochem; 2001; 81(1):172-83. PubMed ID: 11180407
[TBL] [Abstract][Full Text] [Related]
17. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
18. HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function.
Di Stefano V; Blandino G; Sacchi A; Soddu S; D'Orazi G
Oncogene; 2004 Jul; 23(30):5185-92. PubMed ID: 15122315
[TBL] [Abstract][Full Text] [Related]
19. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis.
Kondo S; Barna BP; Kondo Y; Tanaka Y; Casey G; Liu J; Morimura T; Kaakaji R; Peterson JW; Werbel B; Barnett GH
Oncogene; 1996 Sep; 13(6):1279-85. PubMed ID: 8808702
[TBL] [Abstract][Full Text] [Related]
20. Identification of a CK2 phosphorylation site in mdm2.
Götz C; Kartarius S; Scholtes P; Nastainczyk W; Montenarh M
Eur J Biochem; 1999 Dec; 266(2):493-501. PubMed ID: 10561590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
